Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
How should Abasaglar® (insulin glargine) be administered and dosed?
Abasaglar should be administered subcutaneously, once daily the same time each day.
Check the insulin label to avoid medication errors between Abasaglar and other insulins.1
Inspect Abasaglar and only use it if the solution is
- with no solid particles visible, and
- of water-like consistency.1
Inject between 1 and 80 units of Abasaglar per injection.2
Administer subcutaneously into the abdominal area, thigh, or deltoid.3
Rotate injection sites within the same region to reduce the risk of lipodystrophy and cutaneous amyloidosis.1
Do not dilute or mix Abasaglar with any other insulin or or medicinal products. Mixing or diluting can change its time/action profile and mixing can cause precipitation.1
Do not administrate Abasaglar intravenously.
The prolonged duration of action of insulin glargine is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.1
Inject Abasaglar at any time of day.1
Adapt the dose regimen of Abasaglar based on the individual’s needs.1
Perform dosage adjustments of Abasaglar under medical supervision and with appropriate glucose monitoring.
Dosage adjustments may be needed with
- changes in physical activity
- changes in meal patterns
- episodes of acute illness, or
- changes in renal or hepatic function.1
1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Abasaglar [instructions for use]. Eli Lilly Nederland B.V., The Netherlands .
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: July 22, 2019